VNT-101

• Description :

  VNT-101 is an orally active influenza A (IAV) inhibitor. VNT-101 disrupts NP-NP PPI to block NP oligomerization and destabilize the viral ribonucleoprotein (RNP) complex, with potent antiviral activity across multiple influenza A subtypes. VNT-101 exhibits EC50 values of 4-5 nM in cellular cytopathic effect (CPE) assay, 4-8 nM in neuraminidase (NA) assay, and 21-45 nM in RNP assay. VNT-101 demonstrates robust in vivo antiviral efficacy in mice infected with lethal H1N1 virus. VNT-101 can be used for the study of influenza A infection[1].

• UNSPSC :

  12352005

• Target :

  Influenza Virus

• Related Pathways :

  Anti-infection

• Field of Research :

  Infection

• Purity :

  99.51

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  COC[C@]1(COC[C@H](O1)COC2=CC=C(C(C=C3C(N)=O)=C(C(F)(F)F)NC3=O)C=C2)C

• Molecular Formula :

  C21H23F3N2O6

• Molecular Weight :

  456.41

• References & Citations :

  [1]Taft BR, et al. Discovery and Optimization of a Novel Series of Influenza A Virus Replication Inhibitors Targeting the Nucleoprotein Protein-Protein Interaction. J Med Chem. 2025 Aug 14;68 (15) :16349-16370.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [2894060-67-2]